Spain Antacids Market Overview, 2031

Key Insights

• According to the research report, "Spain Antacids Market Outlook, 2031," published by Bonafide Research, the Spain Antacids Market is anticipated to grow at more than 3.91% CAGR from 2026 to 2031.
• The antacids market in Spain is undergoing a significant transformation driven by formulation breakthroughs, specifically the shift toward multi-action combination therapies and natural alternatives. Traditional single-action mineral antacids are increasingly losing ground to advanced alginate formulations paired with mucosal protectors, such as sodium alginate combined with hyaluronic acid and chondroitin sulfate. Brands like Alusogen and specialized lines of Gaviscon have led this innovation, offering products that form a physical raft barrier over stomach contents while healing eroded esophageal tissue. Furthermore, Spanish consumer preferences lean heavily toward non-systemic options, with natural and botanical gastrointestinal remedies generating over €45 million in annual sales across Spanish community pharmacies.
• High underlying prevalence of Gastroesophageal Reflux Disease (GERD) and lifestyle-induced heartburn continues to fuel robust, year-round demand for self-care options across the country. According to data from the Sociedad Española de Patología Digestiva (SEPD), approximately 32% of the adult population in Spain experiences heartburn or acid regurgitation at least once a month, with 10% to 12% suffering from symptoms weekly. Late evening dining habits common in Spanish culture exacerbate these digestive issues, establishing antacids as an essential household staple. Consequently, Spain's network of over 22,000 community pharmacies distributes more than 18 million individual packages of OTC antacids and acid-suppressing remedies every year.

Market Outlook

• Product delivery systems are evolving rapidly toward convenience and on-the-go portability to suit modern consumer lifestyles. Manufacturers in Spain are prioritizing single-dose liquid sachets, chewable soft gels, and waterless fast-dissolving oral strips over conventional bulky tablets and glass liquid bottles. These convenient form factors allow consumers to manage acid reflux events immediately after meals outside the home, driving high-margin growth in impulse pharmacy purchases and widening brand differentiation on retail shelves.
• Health authorities have implemented stricter monitoring and prescription controls on the long-term use of Proton Pump Inhibitors (PPIs) such as omeprazole due to growing medical concerns over chronic risks like bone density loss and renal complications. This regulatory push has successfully redirected patients with mild-to-moderate or episodic acid reflux away from daily prescription PPI usage back toward rapid-acting OTC antacids, alginates, and non-prescription H2 blockers, stimulating sustained organic volume growth across retail channels.
• The next generation of Spanish antacids is expected to feature dual-action remedies combining fast-acting buffering agents with targeted probiotics and prebiotics designed to support the gastric microbiome and soothe stomach linings long-term. Navigated by key industry bodies like the SEPD and ANEFP (Asociación para el Autocuidado de la Salud), this competitive market features prominent global and domestic manufacturers including Reckitt Benckiser (Gaviscon), Bayer (Rennie), Sanofi, Laboratorios Almirall, and FAES Farma.

Market Dynamics

Driver: Rising demand for digestive/heartburn relief
Lifestyle factors and demand for self-care are supporting Spain’s digestive-remedies market, including antacids. Euromonitor notes that lifestyle factors are driving category growth, while the rebound in travel and tourism is also expected to support demand for digestive remedies.
Challenge: Strong price and substitution pressure
The market faces increasing competition from lower-priced products and alternative digestive remedies. Euromonitor highlights lower pricing and greater retailer investment as important competitive factors, while probiotics and herbal products are emerging as alternatives to conventional digestive medicines.
Trend: Shift toward liquid and combination/alginate formulations
Liquid antacids are showing stronger growth than traditional tablet formats, while alginate-based products are relevant to reflux-focused formulations. In Spain, tablets represented majority of antacid-market revenue in 2025, but gummies were identified as the fastest-growing format through 2033.

Procurement and Industry Impact

• Antacid manufacturers need reliable procurement of active ingredients such as calcium-, magnesium- and aluminium-based compounds, while alginate-based products create an additional dependency on alginate supply. Spain's broader alginate market was estimated at US$20.4 million in 2025, with a forecast 4.3% CAGR to 2033; imports of alginates into Spain also increased in 2024. Procurement teams should prioritize dual sourcing, supplier qualification and inventory buffers for critical APIs/excipients.
• Spain's medicines regulator AEMPS reported that 1,532 of 32,893 authorized medicine presentations (4.6%) experienced supply problems in H1 2023. The main causes included plant-capacity constraints, increased demand and manufacturing problems.
• The Spanish digestive-remedies market is seeing greater participation from grocery retailers, while competitive pricing is helping leading brands maintain their position. This creates pressure on manufacturers to control API, packaging and contract-manufacturing costs while maintaining regulatory and quality standards. Procurement is likely to focus increasingly on competitive tendering, local/EU suppliers, contract manufacturing and packaging-cost reduction, particularly for mature tablet products.

Segment Analysis

Spain Antacids Market By Drug Class
• Acid neutralizers remain an important component of gastrointestinal self-care in Spain because they provide direct, short-term relief by neutralizing gastric acid. Calcium, magnesium and aluminium-based ingredients are commonly used approaches, while combinations with alginates or other ingredients can broaden symptom coverage. A Spanish community-pharmacy study involving 1,360 patients across 134 pharmacies found antacid monotherapy was the most frequently requested treatment, accounting for 70.1% of requested therapies.
• Proton Pump Inhibitors (PPIs) occupy a more sustained acid-suppression position because they inhibit gastric acid secretion rather than neutralizing acid already present. Omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole are recognized within Spain's A02B classification for peptic-ulcer and gastroesophageal-reflux medicines. Their relevance is particularly strong for recurrent GERD, reflux oesophagitis and ulcer-related conditions.
• H2 antagonists provide another acid-suppression mechanism by blocking histamine H2 receptors on gastric acid-producing cells. Their role is more targeted than conventional antacids because they reduce acid production rather than neutralizing existing acid. Spain's medicines classification places H2-receptor antagonists within the A02B category for peptic-ulcer and gastroesophageal-reflux treatment.
• Pro-motility agents represent a specialized gastrointestinal-treatment segment because their principal role is to influence gastrointestinal movement rather than directly reduce gastric acidity. They can be relevant when reflux symptoms coexist with delayed gastric emptying or functional motility problems. Consequently, their use is more clinically directed than the routine pharmacy-based consumption of antacids.
• Combination formulations have particular relevance in Spain because consumers frequently present with overlapping upper-GI symptoms. The Spanish community-pharmacy study found that 13.2% of requested treatments consisted of alginate-antacid combinations, while patients receiving such combinations were more likely to consider them effective for symptom relief. This supports the role of multi-mechanism products combining acid neutralization with a reflux-barrier effect.

Spain Antacids Market By Dosage Form
• Tablets and chewables are well suited to Spain's self-care environment because they offer portable, standardized dosing and convenient administration. Chewable formats are particularly useful for consumers seeking immediate treatment after meals or when away from home. Their straightforward administration also makes them suitable for symptom-driven purchases through community pharmacies.
• Liquid suspensions provide an alternative for consumers who prefer liquids or experience difficulty swallowing solid medicines. They allow manufacturers to formulate combinations of antacid ingredients and can provide a smooth administration experience. Accurate dose measurement, suspension stability and flavour remain important considerations for consumer acceptance.
• Powders offer a non-tablet administration option that can be designed for rapid dispersion following preparation. They may appeal to consumers seeking flexibility in how gastrointestinal medicines are administered. However, the additional preparation step means packaging, moisture protection and clear dosing instructions become important product attributes.
• Gels and syrups provide smooth swallowing and are particularly relevant for reflux-barrier formulations. Alginates can form a physical barrier that helps limit the movement of gastric contents toward the oesophagus, giving gel-like products a mechanism beyond simple acid neutralization. The Spanish community-pharmacy evidence showing use of alginate-antacid combinations supports the relevance of this approach.
• Gummies and other formats represent a more consumer-oriented development opportunity. Gummies can improve portability and provide a familiar administration experience, although conventional antacid ingredients can require relatively high active quantities, creating challenges involving flavour, texture and stability. Other formats such as effervescent or rapidly dispersible preparations can differentiate products through convenience and ease of use.

Spain Antacids Market By Indication
• Gastroesophageal Reflux Disease (GERD) is an important driver of Spain's broader acid-control market. A Spanish community-pharmacy study of 1,360 patients found that 31.8% presented with retrosternal symptoms and 54.3% had overlapping epigastric and retrosternal symptoms, illustrating the frequency of reflux-type complaints among people seeking pharmacy advice. PPI use was particularly common among patients with overlapping symptoms.
• Heartburn is a major self-care indication because consumers can usually recognize the characteristic burning or retrosternal discomfort and seek treatment directly from a pharmacy. In the Spanish pharmacy study, antacid monotherapy was requested by 70.1% of participants seeking treatment, demonstrating the importance of rapid symptomatic treatment in community-pharmacy practice. Among patients with epigastric symptoms, antacid monotherapy represented 89.1% of requested treatments.
• Peptic ulcer represents a more clinically supervised indication than routine heartburn. Acid suppression with PPIs is particularly relevant because Spanish medicines classification specifically places PPIs within the A02B group covering peptic-ulcer disease and gastroesophageal reflux. AEMPS identifies PPI indications including gastric and duodenal ulcers, reflux disease, reflux oesophagitis and NSAID-associated ulcers. Conventional antacids are therefore more appropriately viewed as symptomatic-relief products rather than substitutes for cause-directed ulcer treatment.
• Others include dyspepsia, acid indigestion, gastritis-related discomfort, epigastric burning and other upper-GI symptoms. The Spanish pharmacy study found 13.9% of patients had predominantly epigastric symptoms, while the majority had overlapping symptom patterns. This broad symptom mix creates opportunities for products that combine antacid, alginate and other complementary mechanisms.

Spain Antacids Market By Distribution Channel
• Retail pharmacies are a particularly important channel because Spanish community pharmacies function as an accessible point for consumers seeking advice about upper-GI symptoms and non-prescription treatment. The 2022 Spanish study covered 134 community pharmacies, demonstrating the importance of pharmacy-based management for people seeking treatment advice or requesting OTC gastrointestinal medicines.
• Hospital pharmacies serve a more clinically directed segment involving patients with diagnosed GERD complications, peptic ulcers, severe reflux disease and other gastrointestinal disorders. Hospital-channel demand is therefore more strongly influenced by physician diagnosis, institutional treatment protocols and prescribed acid-suppressive therapies than by spontaneous consumer purchases.
• Online pharmacies / E-commerce provide consumers with convenience, product comparison and home delivery, particularly for repeat purchases of familiar gastrointestinal products. However, medicine authenticity and regulatory compliance remain important because Spain's pharmaceutical system is regulated by the Spanish Agency of Medicines and Medical Devices (AEMPS). The agency's medicine framework includes authorized medicines and safety surveillance, making regulated supply an important consideration for online purchasing.
• The community-pharmacy channel remains especially valuable for symptom-led gastrointestinal treatment because pharmacists can distinguish between occasional heartburn appropriate for self-care and symptoms requiring medical evaluation. In the Spanish study, 64.9% of participants had already used some treatment before visiting the pharmacy, and 62.1% of those who had previously treated themselves had used non-prescribed treatment. This highlights the strong self-medication component of Spain's upper-GI treatment environment.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Antacids Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Acid Neutralizers
• Proton Pump Inhibitors (PPIs)
• H2 Antagonists
• Pro-Motility Agents
• Combination Formulations

By Dosage Form
• Tablets & Chewables
• Liquid Suspensions
• Powders
• Gels & Syrups
• Gummies & Other

By Indication
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic Ulcer
• Others

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies / E-Commerce